Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT02169895 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Start date: September 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg (Prolopa® 100-25)

NCT ID: NCT02169479 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Start date: September 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg (Sinemet® 100/25)

NCT ID: NCT02169466 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Start date: January 2009
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide 25 mg (Madopar HBS).

NCT ID: NCT02169453 Completed - Clinical trials for Parkinson's Disease (PD)

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Start date: October 2008
Phase: Phase 1
Study type: Interventional

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg (Sinemet® CR 100/25)

NCT ID: NCT02169440 Completed - Clinical trials for Parkinson's Disease (PD)

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.

NCT ID: NCT02169427 Completed - Clinical trials for Parkinson's Disease (PD)

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Start date: March 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.

NCT ID: NCT02169414 Completed - Clinical trials for Parkinson's Disease (PD)

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a single dose of immediate-release levodopa/benserazide 100/25 mg.

NCT ID: NCT02168842 Completed - Parkinson Disease Clinical Trials

Efficacy of Isradipine in Early Parkinson Disease

Start date: November 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

NCT ID: NCT02168504 Completed - Parkinson's Disease Clinical Trials

Electromyography Signals as Biomarkers for Parkinson's Disease

Start date: June 2014
Phase: N/A
Study type: Observational

A simple, painless and reliable method to detect Parkinson's disease at an early stage is very important to patients, doctors and researchers. Doctors want to help patients early, and scientists want to select patients for their research who will help in development of better drugs. We hope that the changes in electrical activity of hand muscles during handwriting will help in early detection of this disease.

NCT ID: NCT02157714 Completed - Parkinson's Disease Clinical Trials

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Start date: June 2014
Phase: Phase 1
Study type: Interventional

This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.